Omega-3 Fatty Acids Prevent Pressure Overload-Induced Cardiac Fibrosis Through Activation of Cyclic GMP/Protein Kinase G Signaling in Cardiac Fibroblasts
Heart failure is the leading reason for hospital admissions and is the most expensive Medicare expenditure. About half of heart failure cases are due to diastolic dysfunction. One of the main causes of diastolic dysfunction is cardiac fibrosis, and no therapies are available to prevent or treat cardiac fibrosis. Transforming growth factor-␤1-induced cardiac fibroblast transformation and proliferation are the key events leading to cardiac fibrosis. This study shows that -3 polyunsaturated fatty acids prevent pressure overloadinduced cardiac fibrosis and subsequent cardiac dysfunction. This study also demonstrates that in cardiac fibroblasts, eicosapentaenoic acid and docosahexaenoic acid increase cyclic GMP levels by increasing phosphorylated endothelial nitric oxide synthase and endothelial nitric oxide synthase protein levels and nitric oxide production, and they exert their antifibrotic effect through activation of the cyclic GMP/protein kinase G pathway and subsequent blocking of transforming growth factor-␤1-induced nuclear translocation of phospho-Smad2 and phospho-Smad3. This study defines the beneficial effects of -3 polyunsaturated fatty acids on cardiac fibrosis and cardiac dysfunction and clarifies the underlying mechanisms. In addition, this study provides the basis for extending the application of -3 polyunsaturated fatty acids, which appear to be exceptionally safe and well tolerated, to the prevention of cardiac fibrosis. See p 584.
Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury
Accumulating reports have demonstrated the important role of an inflammation-induced multiple-protein complex called the inflammasome in the field of immunology. To date, however, little is known about the role of inflammasome in the pathophysiology of myocardial ischemia/reperfusion (I/R) injury. Activation of inflammasome is triggered by tissue damage and leads to the processing of prointerleukin-1␤ (interleukin-1␤) to its mature form. In the present study, we demonstrate that inflammasome activation in cardiac fibroblasts, but not in cardiomyocytes, is crucially involved in the initial inflammatory response after myocardial I/R injury. We found that inflammasomes are formed by I/R and that its subsequent activation of inflammasomes leads to interleukin-1␤ production, resulting in inflammatory responses such as inflammatory cell infiltration and cytokine expression in the heart. In mice deficient for apoptosis-associated speck-like adaptor protein and caspase-1, these inflammatory responses and subsequent injuries, including infarct development and myocardial fibrosis and dysfunction, were markedly diminished. Bone marrow transplantation experiments using apoptosis-associated speck-like adaptor protein-deficient mice revealed that inflammasome activation in bone marrow cells and myocardial resident cells such as cardiomyocytes or cardiac fibroblasts plays an important role in myocardial I/R injury. In vitro experiments revealed that hypoxia/reoxygenation stimulated inflammasome activation in cardiac fibroblasts, but not in cardiomyocytes, and that hypoxia/reoxygenation-induced activation was mediated through reactive oxygen species production and potassium efflux. Our results demonstrate the molecular basis for the initial inflammatory response after I/R and suggest that the inflammasome is a potential novel therapeutic target for preventing myocardial I/R injury. See p 594.
Inhaled Nitrite Reverses Hemolysis-Induced Pulmonary Vasoconstriction in Newborn Lambs Without Blood Participation
Nitric oxide (NO) is a tonic vasodilator in the normal circulation. Free hemoglobin in the plasma, as occurs during hemolysis, rapidly scavenges NO, resulting in decreased perivascular NO concentrations and vasoconstriction. Recent reports suggest that the pulmonary vasculature is especially sensitive to hemolysis as demonstrated by the increased incidence of pulmonary hypertension in patients with hemolytic disorders. In the present studies in newborn sheep, we found that infusion of hemolyzed blood increased resistance to pulmonary blood flow with little or no systemic effect, indicating that the pulmonary vasculature is particularly sensitive to the effects of hemolysis. Oxidation of plasma hemoglobin to methemoglobin, which does not scavenge NO, prevented the pulmonary hypertension caused by hemolysis. We have shown previously that inhaling an aerosol containing nitrite reverses pulmonary hypertension in newborn lambs, presumably by conversion to NO. The present studies now show that the transformation of nitrite to NO does not depend on nitrite reacting with hemoglobin in red cells as previously proposed but rather must occur in pulmonary airways and tissues. Free NO released within lung parenchymal tissues would then reach smooth muscle of lung resistance vessels and escape scavenging by erythrocytic or plasma hemoglobin. The studies demonstrate again that inhaled nitrite is an effective pulmonary vasodilator and point 569
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Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
The lymphatic vascular system is crucial for the regulation of tissue fluid homeostasis, fat metabolism, and elicitation of immune responses. Lymphatic dysfunction, either resulting from gene alterations or secondary to damage to the lymph vessels, may lead to lymphedema, a debilitating condition characterized by chronic tissue edema, impaired immunity, and accumulation of subcutaneous fat. Lymphedema is a common and incurable problem. Interestingly, during recent years, application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema in small animal models. The aim of the present study was to evaluate the potential of growth factor therapy in a clinically relevant novel large animal model. Lymphedema patients have recurrent infections and thus would benefit from both functional lymphatic vessels and lymph nodes. In an attempt to restore the lymphatic anatomy, we combined growth factor therapy with lymph node transfer. Interestingly the lymph nodes transduced with vascular endothelial growth factors (C and D) survived and formed both afferent and efferent connections with the preexisting lymphatic vessel network, whereas the control vector-treated nodes regressed. We compared the effect of 2 different endothelial growth factors to select the best candidate for the clinical trials. Combining autologous lymph node transfer and therapeutic growth factors provides a promising tool for the curative treatment of lymphatic vessel dysfunction after infection, surgery, or radiation therapy. See p 613.
Augmented Expression and Activity of Extracellular Matrix-Degrading Enzymes in Regions of Low Endothelial Shear Stress Colocalize With Coronary Atheromata With Thin Fibrous Caps in Pigs
This study explores the molecular mechanisms that determine the localized formation of thin-capped fibroatheromas in the coronary arteries of diabetic, hyperlipidemic swine. Local endothelial shear stress was calculated in vivo with a combination of intravascular ultrasound, coronary angiography, and computational fluid dynamics in plaque-free subsegments of interest at baseline (week 23). The messenger RNA and protein expression and the elastolytic activity of selected matrix-degrading proteases were assessed in these subsegments at follow-up (week 30), demonstrating that (1) subsegments with low preceding endothelial shear stress at week 23 had reduced endothelial cell coverage and enhanced lipid accumulation and inflammation at week 30; (2) these subsegments showed increased expression of messenger RNAs encoding matrix metalloproteinase-2, -9, and -12 and cathepsins K and S relative to their endogenous inhibitors and increased elastolytic activity; and (3) expression of these enzymes correlated positively with the severity of internal elastic lamina fragmentation. We further showed that thin-capped atheromata developed in regions with lower preceding endothelial shear stress and had reduced endothelial coverage, intense lipid and inflammatory cell accumulation, enhanced messenger RNA expression of matrix metalloproteinases and cathepsins, heightened elastolytic activity, and severe internal elastic lamina fragmentation. Our results provide new insight into the hemodynamic and molecular mechanisms of regional formation of plaques with thin fibrous cap and indicate that the in vivo understanding of local endothelial shear stress may allow identification of a high-risk plaque in its early stages of development. Early identification of a high-risk plaque may provide a rationale for selective local coronary interventions, supplemented by an intensive systemic pharmacological approach, to avert future acute coronary events. See p 621.
Microsomal Prostaglandin E 2 Synthase-1 Modulates the Response to Vascular Injury
Nonsteroidal antiinflammatory drugs specific for the inhibition of cyclooxygenase-2 (COX-2) confer a risk of myocardial infarction and stroke. Microsomal (m) prostaglandin (PG) E 2 synthase (S)-1 represents an alternative antiinflammatory target downstream of COX-2. Inhibition of mPGES-1 may be less likely to predispose patients to thrombotic events than inhibition of COX-2. Despite the risk of myocardial infarction conferred by celecoxib in placebocontrolled trials, preliminary evidence suggests that in patients receiving platelet inhibitors to limit this risk, restenosis might be reduced by this purposefully designed nonsteroidal antiinflammatory drug selective for inhibition of COX-2. Here, we demonstrate that deletion of mPGES-1 in mice attenuates neointimal hyperplasia after vascular injury. Both suppression of PGE 2 and rediversion of the accumulated PGH 2 substrate to PGI 2 may contribute to dysregulated expression of tenascin-C, an extracellular matrix glycoprotein, resulting in impaired vascular smooth muscle cell migration and proliferation in the knockouts. These studies raise the possibility of mPGES-1 inhibition as a strategy to limit restenosis after percutaneous coronary intervention. However, a limitation may prove to be the contrasting effect on myocardial remodeling after coronary ligation. Although mPGES-1 inhibitors might be expected to confer a diminished risk of myocardial infarction and mortality after myocardial infarction compared with COX-2 inhibitors, the safety and efficacy of these compounds in the setting of percutaneous coronary intervention remain to be determined. The therapeutic potential of locally delivered mPGES-1 inhibitors as an adjuvant for percutaneous coronary intervention merits further consideration. See p 631.
